长效胰岛素联合二甲双胍、利拉鲁肽对肥胖2型糖尿病患者血糖水平、腹围的影响

长效胰岛素联合二甲双胍、利拉鲁肽对肥胖2型糖尿病患者血糖水平、腹围的影响

作者：王梅丽周小智符金香陈雨郭剑平

来源：《中国医学创新》2023年第36期

【摘要】目的：分析長效胰岛素联合二甲双胍、利拉鲁肽对肥胖2型糖尿病（T2DM）患者血糖水平、腹围的影响。方法：选取吉安市中心人民医院2022年4月—2023年3月收治的80例肥胖T2DM患者为研究对象，采用随机数字表法分为对照组[n=40，接受二甲双胍联合

精蛋白人胰岛素混合注射液（50R）治疗]和观察组[n=40，接受二甲双胍、长效胰岛素（甘精胰岛素）联合利拉鲁肽治疗]。比较两组患者血糖水平、腹围、低血糖发生率及血糖控制达标率。结果：治疗后两组糖化血红蛋白（HbA1c）、空腹血糖（FPG）及餐后2小时血糖（2 h PG）水平均显著低于治疗前，且观察组HbA1c、FPG及2 h PG水平均显著低于对照组，差异均有统计学意义（P<0.05）；治疗后观察组腹围显著低于对照组，差异有统计学意义

（P<0.05）；治疗期间，观察组出现2例低血糖，对照组出现8例低血糖，观察组低血糖发生率显著低于对照组，差异有统计学意义（P<0.05）；观察组血糖控制达标率显著高于对照组，差异有统计学意义（P<0.05）。结论：长效胰岛素联合二甲双胍、利拉鲁肽治疗肥胖T2DM患者的效果显著，可下调患者血糖水平，减小腹围，且低血糖发生率较低。

【关键词】 2型糖尿病预混胰岛素长效胰岛素利拉鲁肽血糖腹围低血糖

Effects of Long-acting Insulin Combined with Metformin and Liraglutide on Blood Glucose Level and Abdomen Circumference in Obesity Patients with Type 2 Diabetes Mellitus/WANG Meili， ZHOU Xiaozhi， FU Jinxiang， CHEN Yu， GUO Jianping. //Medical Innovation of China， 2023， 20（36）： 0-025

[Abstract] Objective： To analyze the effects of long-acting insulin combined with Metformin and Liraglutide on blood glucose level and abdomen circumference in obesity patients with type 2 diabetes mellitus （T2DM）. Method：A total of 80 obesity patients with T2DM admitted to Ji’an Central Hospital from April 2022 to March 2023 were selected as the study objects， and were divided into control group [n=40， treated with Metformin combined with Mixed Protamine Human Insulin Injection （50R）] and observation group [n=40， treated with Metformin， long-acting insulin （Insulin Glargine） and Liraglutide] according to random number table method. Blood glucose level， abdomen circumference， incidence of hypoglycemia and the rate of blood glucose control up to the standard were compared between the two groups. Result： After treatment， the levels of glycosylated hemoglobin （HbA1c）， fasting plasma glucose （FPG） and 2 h postprandial blood glucose （2 h PG） in both groups were significantly lower than those before treatment， and the levels of HbA1c， FPG and 2 h PG in observation group were significantly lower than those in control group， the differences were statistically significant （P<0.05）. After treatment， abdomen circumference of observation group was significantly lower than that of control group， the difference was statistically significant （P<0.05）. During treatment， there were 2 cases of hypoglycemia in the observation group and 8 cases of hypoglycemia in the control group. The incidence of hypoglycemia in the observation group was significantly lower than that in the control group， the difference was statistically significant （P<0.05）. The rate of blood glucose control up to the standard of the observation group was significantly higher than that of the control group， the difference was statistically significant （P<0.05）. Conclusion： Long-acting insulin combined with Metformin and Liraglutide has a significant effect in the treatment of obesity patients with T2DM，